2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
NETWORK
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Classical hematology
1
Conditions
Marijuana Abuse
3
Neoplasms
2
Epilepsy
2
Tourette Syndrome
1
Stress Disorders, Post-Traumatic
1
Sleep Initiation and Maintenance Disorders
1
Severe Acute Respiratory Syndrome
1
Seizures
1
Parkinson Disease
1
Pancreatic Cancer Non-resectable
1
Pain
1
Opioid-Related Disorders
1
Neurodevelopmental Disorders
1
Multiple Sclerosis
1
Marijuana Use
1
Inflammatory Bowel Diseases
1
Hepatitis C
1
Glaucoma
1
Fibromyalgia
1
Depression
1
Crohn Disease
1
Coronavirus Infections
1
Colitis, Ulcerative
1
Chronic Traumatic Encephalopathy
1
Chronic Pain
1
Carcinoma, Hepatocellular
1
COVID-19
1
Brain Injuries, Traumatic
1
Bipolar Disorder
1
Autistic Disorder
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Medical Marijuana
×
Clear all
NCT05863910
2023-11-30
CAN-RWE
University of Manitoba
Recruiting
500 enrolled
NCT03944447
2022-06-02
OMNI-Can
OMNI Medical Services, LLC
Phase 2
Unknown
200,000 enrolled